Jin Medical agrees US$159.42 million VIE control deal for Huaxia Qiying assets

• Jin Medical entered a Sept. 8, 2026 deal to take contractual control of Huaxia Qiying via a VIE structure.
• Consideration totals USD 159.42 million, payable at closing through issuance of 71,282,488 Class A ordinary shares.
• Target assets center on ginseng bio-resources, research data, rare ginsenosides, and the KB-120 fermentation technology platform.
• Huaxia Qiying has no established commercial operations; assets are intended to support future commercialization and business development.
• Transaction also includes related asset, equity, and receivable transfers, with a potential 622,123-share fallback tied to a delayed equity transfer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jin Medical International Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-098090), on September 08, 2026, and is solely responsible for the information contained therein.